Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.
The U.S. Food and Drug Administration approved Genentech and Blueprint Medicines’ Gavreto (pralsetinib) as a treatment for adults and pediatric patients 12 and older who have been diagnosed with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
Roche acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with the disease.
Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).
Swiss pharma giant Roche acquired Ireland’s Inflazome and the company’s NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases.
An experimental Amgen Inc. drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage trial.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
A look at U.S. Food and Drug Administration PDUFA dates for end-of-August and early-September 2020.
A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
